AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting

Phase 2

Phase 3

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Sponsor:

REGENXBIO Inc.

Code:

NCT05693142

Conditions

Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 1+

Healthy Volunteers: Not accepted

Interventions

RGX-202

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by REGENXBIO Inc. on 2025-05-13.